These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10344910)

  • 1. Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France.
    Nuijten M; Hadjadjeba L; Evans C; van den Berg J
    Pharmacoeconomics; 1998 Oct; 14(4):433-45. PubMed ID: 10344910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
    Einarson TR; Addis A; Iskedjian M
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
    Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
    Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
    Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
    Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine versus other anti-depressive agents for depression.
    Omori IM; Watanabe N; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006114. PubMed ID: 20238342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany.
    Kulp W; von der Schulenburg JM; Greiner W
    Eur J Health Econ; 2005 Dec; 6(4):317-21. PubMed ID: 16267659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?
    Ashford JJ
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():27-31. PubMed ID: 7622820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
    Machado M; Iskedjian M; Ruiz IA; Einarson TR
    Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic studies of antidepressants: focus on venlafaxine.
    Woods SW
    Depress Anxiety; 2000; 12 Suppl 1():102-9. PubMed ID: 11098423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit analysis of newer versus older antidepressants--pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants.
    Laux G
    Pharmacopsychiatry; 2001 Jan; 34(1):1-5. PubMed ID: 11229615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and safety of fluvoxamine and other antidepressants.
    Westenberg HG; Sandner C
    Int J Clin Pract; 2006 Apr; 60(4):482-91. PubMed ID: 16620364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
    Kendrick T; Peveler R; Longworth L; Baldwin D; Moore M; Chatwin J; Thornett A; Goddard J; Campbell M; Smith H; Buxton M; Thompson C
    Br J Psychiatry; 2006 Apr; 188():337-45. PubMed ID: 16582060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder.
    Sobocki P; Ekman M; Ovanfors A; Khandker R; Jönsson B
    Int J Clin Pract; 2008 Apr; 62(4):623-32. PubMed ID: 18284439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
    Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
    J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM
    Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoxetine tenth anniversary update: the progress continues.
    Stokes PE; Holtz A
    Clin Ther; 1997; 19(5):1135-250. PubMed ID: 9385500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sertraline. A pharmacoeconomic evaluation of its use in depression.
    Davis R; Wilde MI
    Pharmacoeconomics; 1996 Oct; 10(4):409-31. PubMed ID: 10184609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.